Over the past decade, improvements in the molecular profiling of NSCLC have led to a more profound understanding of the oncogenic drivers, with EGFR mutations emerging as one of the most important actionable targets for the use of precision therapy [4]. Here, EGFR is linked to non-small cell lung carcinoma.